Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2020-G000-328 Open Label Extension Study of 23 mg Donepezil SR in Moderate to Severe Alzheimer's Disease
2006-004890-93Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of donepezil in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd. Primary endpoints: Long-term safety of 23 mg donepezil SR and Long-term efficacy of 23 mg donepezil SR. Started Feb 2008; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-004890-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004890-93.